Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00361881 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis

A Phase 3 study of Herpes Labialis, sponsored by Medivir.

Completed
Registry status
Phase 3
Development phase
1,443
Enrollment target
1
Study location

NCT00361881 is a Phase 3 study of Herpes Labialis that has completed, run by Medivir. The registered enrollment target is 1,443 participants, above the 822-participant average among 6 other Herpes Labialis trials with a reported enrollment target (76% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00361881, a Phase 3 study of Herpes Labialis, has completed, sponsored by Medivir.

COMPLETED
Registry status
Phase 3
Development phase
1,443 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether ME-609 is more efficient than acyclovir and placebo for the treatment of recurrent herpes labialis.

Conditions Studied

Herpes Labialis

Interventions

  • DRUG Vehicle
  • DRUG ME-609
  • DRUG acyclovir in ME-609 vehicle

Study Locations (1)

South Carolina

  • Coastal Caroline Research Center - Mt. Pleasant

Trial Details

FieldValue
Enrollment Target 1,443 participants
Start Date 2006-07
Est. Completion 2007-12
Phase Phase 3

Sponsor

Medivir

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00361881

The ClinicalTrials.gov registry entry for NCT00361881 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,443 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 822-participant average among 6 other Herpes Labialis trials with a reported enrollment target (76% higher). The listed sponsor is Medivir, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Herpes Labialis appearing as the primary indexed condition, and to 3 interventions - of which Vehicle is the first listed.

NCT00361881 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT00361881 about?

NCT00361881 is a clinical study titled "Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis". The purpose of this study is to determine whether ME-609 is more efficient than acyclovir and placebo for the treatment of recurrent herpes labialis.

What is the current status of trial NCT00361881?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,443 participants. The study started on 2006-07. Estimated completion is 2007-12.

What conditions does trial NCT00361881 study?

This clinical trial studies the following conditions: Herpes Labialis.

What interventions are being tested in trial NCT00361881?

The interventions under investigation include: Vehicle (DRUG), ME-609 (DRUG), acyclovir in ME-609 vehicle (DRUG).

Who is sponsoring clinical trial NCT00361881?

This trial is sponsored by Medivir, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00361881 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Herpes Labialis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Herpes Labialis

All registered trials for this condition

South Carolina

All trials with a study site in South Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.